Cost-effective treatment of acute coronary syndromes-IIB or not IIB?

Eur Heart J. 1999 Sep;20(17):1217-9. doi: 10.1053/euhj.1999.1637.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Angina, Unstable / drug therapy
  • Angina, Unstable / economics*
  • Cost-Benefit Analysis
  • Drug Therapy, Combination
  • Fibrinolytic Agents / therapeutic use
  • Heparin / therapeutic use
  • Humans
  • Myocardial Infarction / drug therapy
  • Myocardial Infarction / economics*
  • Platelet Aggregation Inhibitors / economics*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Retrospective Studies
  • Switzerland
  • Tirofiban
  • Tyrosine / analogs & derivatives*
  • Tyrosine / economics
  • Tyrosine / therapeutic use

Substances

  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors
  • Tyrosine
  • Heparin
  • Tirofiban